PRELID3BP5

Across TCGA pan-cancer cohorts, PRELID3BP5 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of PRELID3BP5’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PRELID3BP5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRELID3BP5 is over-expressed in tumor.

KIRC, LUSC, and LUAD are the cancer types where PRELID3BP5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRELID3BP5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.037	<.001	8	view →
LUSC	All	All	+0.094	.002	5	view →
LUAD	All	All	+0.132	<.001	4	view →
HNSC	Male	All	+0.037	.004	4	view →
THCA	All	IV	+0.155	.033	3	view →
LIHC	All	II,III,IV	+0.070	.015	3	view →
CHOL	All	All	+0.188	.015	2	view →
KIRP	Male	All	+0.052	.036	2	view →
BRCA	Female	All	+0.034	.040	2	view →
STAD	Male	All	+0.048	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

PRELID3BP5–KIRC

Open the KIRC breakdown →